Core Viewpoint - TC BioPharm is executing a non-binding letter of intent to acquire a commercial-stage ophthalmic pharmaceutical company focused on therapies for glaucoma and ocular hypertension, aiming to diversify its therapeutic platform and enhance shareholder value [1][3][4] Company Overview - TC BioPharm is a clinical-stage biotechnology company developing gamma-delta T cell therapies for cancer, with a focus on acute myeloid leukemia [5][6] - The company is recognized as a leader in developing gamma-delta T cell therapies and is conducting pivotal clinical trials [6] Acquisition Details - The acquisition will be an all-stock transaction, allowing TC BioPharm to acquire 100% of the target company [3] - The target company has an FDA-approved once-per-day eye drop for decreasing intraocular pressure and a pipeline of ophthalmology assets [2][3] - The approved product is currently being distributed to 300 physicians for a three-month treatment sample, with a commercial launch expected to generate significant revenue in 2025 [2][4] Market Potential - The global glaucoma market was valued at approximately USD 8.06 billion in 2022 and is projected to reach around USD 12.69 billion by 2032 [4] - The target company's lead product is projected to have a market potential exceeding USD 8 billion within a specific patient population [4] Strategic Implications - The acquisition aligns with TC BioPharm's M&A strategy to expand into new therapeutic areas and acquire later-stage assets that can provide near-term value [3][4] - The management team of the target company has extensive experience in pharmaceutical development, which is expected to drive revenue growth over the next 24 months [4]
TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company